Ecosystem
Beta Site
Search Results
582 items found for "Orphan GPCR"
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Drug Discovery Picks Up the Pace, Stays on Target
drug efficacy analyses, and toxicity studies; technologies that stabilize G protein–coupled receptors (GPCRs Read more at the source #DrGPCR #GPCR #IndustryNews
- Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
Read more at the source #DrGPCR #GPCR #IndustryNews
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
compounds for Charcot-Marie-Tooth type 1A neuropathy (CMT1A) and pain. " Read more at the source #DrGPCR #GPCR
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
Read more at the source #DrGPCR #GPCR #IndustryNews
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
Read more at the source #DrGPCR #GPCR #IndustryNews
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
Read more at the source #DrGPCR #GPCR #IndustryNews
- 4GPCRnet, September 26-29, 2022. Leipzig, Germany
August 2022 "WELCOME 4GPCRnet meeting bringing together four of the biggest GPCR networks in Europe for Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded Read more at the source #DrGPCR #GPCR #IndustryNews
- Discovery On Target, October 17-20, 2022, Boston, USA
Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Reports Second Quarter 2022 Results and Provides Business Update
Read more at the source #DrGPCR #GPCR #IndustryNews
- Effects of Small Molecule Ligands on ACKR3 Receptors
Read more at the source #DrGPCR #GPCR #IndustryNews
- A new Kunitz-type snake toxin family associated with an original mode of interaction with the...
antagonist of the arginine-vasopressin V2 receptor (V2R) and the only unique Kunitz-type peptide active on a GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
August 2022 "Abstract Sigma receptor is a transmembrane non-GPCR protein expressed mainly in the endoplasmic Read more at the source #DrGPCR #GPCR #IndustryNews
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
position as Scientific co-founder LASEREDD Therapeutics" Ross Bathgate Read more at the source #DrGPCR #GPCR
- Sosei Heptares recently hosted their annual Scientific Advisory Board (SAB)
Read more at the source #DrGPCR #GPCR #IndustryNews
- Tectonic Therapeutic Strengthens Leadership Team
Tectonic Therapeutic, Inc. a pre-clinical stage biotechnology company transforming the discovery of novel GPCR-targeted Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex raises $4.2 million in equity financing
issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR1 Read more at the source #DrGPCR #GPCR #IndustryNews
- Novel interaction between neurotrophic factor-α1/carboxypeptidase E and serotonin receptor, 5-HTR1E,
"Protecting neurons from death during oxidative and neuroexcitotoxic stress is key for preventing cognitive dysfunction. We uncovered a novel neuroprotective mechanism involving interaction between neurotrophic factor-α1 (NF-α1/carboxypeptidase E, CPE) and human 5-HTR1E, a G protein-coupled serotonin receptor with no previously known neurological function. Co-immunoprecipitation and pull-down assays confirmed interaction between NFα1/CPE and 5-HTR1E and 125I NF-α1/CPE-binding studies demonstrated saturable, high-affinity binding to 5-HTR1E in stably transfected HEK293 cells (Kd = 13.82 nM). Treatment of 5-HTR1E stable cells with NF-α1/CPE increased pERK 1/2 and pCREB levels which prevented a decrease in pro-survival protein, BCL2, during H2O2-induced oxidative stress. Cell survival assay in β-arrestin Knockout HEK293 cells showed that the NF-α1/CPE-5-HTR1E-mediated protection against oxidative stress was β-arrestin-dependent. Molecular dynamics studies revealed that NF-α1/CPE interacts with 5-HTR1E via 3 salt bridges, stabilized by several hydrogen bonds, independent of the serotonin pocket. Furthermore, after phosphorylating the C-terminal tail and intracellular loop 3 (ICL3) of NF-α1/CPE-5-HTR1E, it recruited β-arrestin1 by forming numerous salt bridges and hydrogen bonds to ICL2 and ICL3, leading to activation of β-arrestin1. Immunofluorescence studies showed 5-HTR1E and NF-α1/CPE are highly expressed and co-localized on cell surface of human hippocampal neurons. Importantly, knock-down of 5-HTR1E in human primary neurons diminished the NF-α1/CPE-mediated protection of these neurons against oxidative stress and glutamate neurotoxicity-induced cell death. Thus, NF-α1/CPE uniquely interacts with serotonin receptor 5-HTR1E to activate the β-arrestin/ERK/CREB/BCL2 pathway to mediate stress-induced neuroprotection." Read full article
- Third Rock pushes newest fund over $1B line as it marks 15 years in venture capital
Read more at the source #DrGPCR #GPCR #IndustryNews
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs Vice-President Drug Discovery, will present Orion’s novel technology for targeting undrugged peptidergic GPCRs discovery platform, one of the fastest drug discovery solutions in the industry for targeting peptidergic GPCRs antagonist, OB-004, demonstrating the ability of this powerful platform to rapidly identify best-in-class GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
- Michel Bouvier appointed Knight of the Ordre national du Québec
Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Presents Clinical And Research Results At ENDO 2022
Read more at the source #DrGPCR #GPCR #IndustryNews
- Targeting the M1 muscarinic receptor in neurodegenerative disease
Translational Sciences Associate Director at Sosei Heptares, recently presented at the Keystone Symposia GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
